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ABSTRACT
Dosimetric audit is required for the improvement of patient safety in radiotherapy and to aid optimization of treatment.
The reassurance that treatment is being delivered in line with accepted standards, that delivered doses are as prescribed
and that quality improvement is enabled is as essential for brachytherapy as it is for the more commonly audited external
beam radiotherapy. Dose measurement in brachytherapy is challenging owing to steep dose gradients and small scales,
especially in the context of an audit. Several different approaches have been taken for audit measurement to date:
thimble and well-type ionization chambers, thermoluminescent detectors, optically stimulated luminescence detectors,
radiochromic film and alanine. In this work, we review all of the dosimetric brachytherapy audits that have been
conducted in recent years, look at current audits in progress and propose required directions for brachytherapy
dosimetric audit in the future. The concern over accurate source strength measurement may be essentially resolved with
modern equipment and calibration methods, but brachytherapy is a rapidly developing field and dosimetric audit must
keep pace.
THE NEED FOR AUDIT
Audit is required in a multitude of scenarios in medicine,
and the term has acquired different meanings over time in
relation to health care quality. Clinical audit, for example,
might involve systematically looking at the procedures for
diagnosis, care and treatment, examining how resources
are used, investigating the effect care has on patient out-
comes, and importantly recognizing audit as a quality
improvement process and not just a monitoring system.
Audit might consider any aspect of infrastructure, pro-
cedure or outcome to ensure safe, effective and best-
practice processes and enable improvements. NHS England
has deﬁned clinical audit as “a way to ﬁnd out if healthcare
is being provided in line with standards”, and importantly
“the aim is to allow quality improvement to take place
where it will be most helpful and will improve outcomes
for patients”.1 Audit therefore needs to be undertaken, and
it needs to be directed appropriately. In this review, we
limit our scope to the speciﬁc consideration of dosimetric
audit of brachytherapy.
In radiotherapy physics, a key component of auditing is to
review the most fundamental of requirements, which is
whether prescribed radiation doses are being accurately
delivered. This might involve testing the dissemination of
dosimetry calibration from national standard laboratories,
verifying dose or dose distribution for particular complex
treatment techniques, or assuring dose delivery for com-
pliance with clinical trial protocols.2 With regard to the
latter, it has been demonstrated that the number of patients
required in a randomized clinical trial may be reduced by
introducing appropriate dosimetry quality assurance (QA),
as the risk of under-powering the study is minimized.3 The
largest dosimetric audit networks at present are operated
by the International Atomic Energy Agency (IAEA),4 the
American Radiological Physics Centre (RPC)5 and in
Europe the European Society for Radiotherapy and On-
cology (ESTRO) Quality Assurance network (EQUAL).6
The reader is directed to the proceedings of a 2010 IAEA
International Symposium on Standards, Applications and
Quality Assurance in Medical Radiation Dosimetry
(IDOS)7 for a number of papers on external beam audit.
There are also many national audit groups, for example, in
the UK, auditing is co-ordinated by the Institute of Physics
and Engineering in Medicine (IPEM) via a number of re-
gional groups.8,9 This network arose following an IPEM co-
ordinated national megavoltage photon beam dosimetry
audit10 and a later national electron beam dosimetry au-
dit.11 In 2012, the IAEA surveyed the worldwide coverage
of dosimetry audit programmes for radiotherapy,12 ﬁnding
audit activity in 45 countries, of which 16 had a mandatory
requirement for participation, but with around one-third of
world radiotherapy centres having no independent assessment.
In the UK, a consortium of professional bodies published “To-
wards Safer Radiotherapy”,13 which recommends that “all cen-
tres should participate in dosimetric audit networks” and that
“comparative audits between departments can provide valuable
opportunities to ensure safe delivery of radiotherapy and con-
sistency of patient outcomes”. The National Health Service
(NHS) National Cancer Peer Review Programme Manual for
Cancer Services: Radiotherapy Measures14 requires centres to
take part in local audit networks. This is typical of publications
from several bodies in recent years suggesting how radiotherapy
could be made safer. Dunscombe,15 has analysed seven author-
itative documents, including “Towards Safer Radiotherapy”, to
ﬁnd commonalities between the recommendations. “Dosimetric
audit” was one of the 12 topics identiﬁed in $3 documents as
being pertinent to the improvement of patient safety in radio-
therapy. Dunscombe15 states that “organizations like the RPC
and EQUAL-ESTRO have had, and continue to have, a huge
positive inﬂuence on the safety and quality of radiotherapy”.
However, Dunscombe15 also discusses that dosimetric audits are
not always carried out appropriately, stating audits should “take
place prior to the ﬁrst clinical use” and enable “testing the device
under conditions other than those used to calibrate it”, citing
a treatment error from Ontario as an example that might be
avoided if audits were optimally used.16
The increasing complexity of radiotherapy planning and delivery
makes dosimetric audits challenging, and it is probably no
longer sufﬁcient to verify only the absolute dose delivery at
a reference point, which had been the standard approach in the
past two decades. Kron et al17 states the focus of current research
is to adapt dosimetry audit for even more diversiﬁed radio-
therapy procedures including image-guided/adaptive radiother-
apy, motion management and brachytherapy. This review
considers the latter, speciﬁcally, physics aspects of dosimetric
audit for brachytherapy, in the radiotherapy clinic.
THE NEED FOR AUDIT IN BRACHYTHERAPY
In comparison with external beam radiotherapy, the physical
processes by which the majority of brachytherapy equipment
calculates and delivers treatment is relatively simple. However,
this does not mean that dosimetric audit is without complexity.
Indeed, the high-dose gradients, orders of magnitude variation
in dose deposition across clinical regions of interest and small
scales, mean measurements to verify absolute dose and dose
distribution are challenging. Haworth et al18 states “to date,
dosimetric audits of high dose rate (HDR) facilities have not
been conducted in Australia despite the high risks associated
with these treatments due to the challenges presented by mea-
suring doses in steep dose gradients”. In the UK, the National
Cancer Peer Review Programme Manual for Cancer Services:
Radiotherapy Measures14 states there is a requirement that “the
department should have taken part in the External Quality
Control programme”, but this is only speciﬁcally listed within
the external beam radiotherapy measures, not within the bra-
chytherapy measures. This may be owing to the lack of avail-
ability of brachytherapy dosimetric audit at that time, difﬁculties
in implementation or prioritization of need. However, in the
more recent NHS England Service Speciﬁcation document for
2013/14 for brachytherapy,19 it is stated that “to ensure that the
services being delivered offer high quality brachytherapy to
patients”, one of the speciﬁc requirements is that “the provider
department must participate in the national inter-departmental
dosimetry audit programme (national audit of HDR
brachytherapy)”.
In the past few years, numerous commercial detectors and
phantoms have been speciﬁcally developed to verify dose dis-
tributions in external beam radiotherapy, partly driven by the
adoption of intensity-modulated radiotherapy and volumetric-
modulated arc therapy (VMAT) techniques. These active detec-
tors might conveniently be adopted for dosimetric audit.20
However, there have been no similar commercial developments
for brachytherapy. Well-type ionization chambers have been
adopted for source strength determination, and commonly ther-
moluminescent detectors (TLDs) have been used for point-dose
measurements, but there is no clear consensus on techniques for
veriﬁcation of dose distribution measurement in brachytherapy.
Many dosimetry systems have been investigated in the past decade
for brachytherapy measurement, including gel dosimetry, TLDs,
semiconductor diodes, ionization chambers, metal oxide semi-
conductor ﬁeld effect transiter (MOSFET) detectors, alanine,
radiochromic ﬁlm, radiochromic plastic, calorimetry and optically
stimulated or radioluminescent detectors.21
The need for dosimetric audit in brachytherapy exactly mirrors
the need in external beam radiotherapy: to detect any errors, to
provide reassurance, to enable improvements and to demon-
strate compliance. There are of course numerous sources of
uncertainty in brachytherapy,22 and there have been previous
errors in brachytherapy delivery,23–26 including well-type
chamber calibration error,27 confusion over units28 and media
reports of at least two incidents involving incorrect dwell
positions.29,30,31 The pace of change in brachytherapy equip-
ment, physics and clinical processes has also been rapid in recent
years with the integration of multimodality 3D imaging, im-
proved dosimetry and treatment planning including patient-
speciﬁc optimization, volume prescribing and new equipment
and applicators.32–34 Treatment planning algorithms in brachy-
therapy might also be on the verge of a step change in complexity
and a move from standard planning to fully ﬂexible optimiza-
tion might have widespread uptake.32–35 To contribute to the
overall quality, safety and reassurance, brachytherapy should be
subjected to the same rigour of local quality checks36 and audit
mechanisms as external beam radiotherapy.
DOSIMETRIC AUDITS IN BRACHYTHERAPY
A systematic review was conducted on journal articles discussing
concepts, research and practices of dosimetric audit in the clinic
for brachytherapy over the past three decades. MEDLINE and
Embase databases were searched, internet search engines utilized
and several brachytherapy experts across the world consulted.
Eight peer-reviewed journal publications were obtained that
presented results of fully completed audits or pilot audits at
several centres, involving dosimetric measurement,18,37–43 and
one concerned with a geometric applicator reconstruction
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audit.44 Two more journal publications presented methodologies
for brachytherapy audit currently in progress,45,46 and the
authors are aware of another two audits currently in progress in
the UK that are not yet described in the literature: a well-type
chamber intercomparison and an alanine dosimetry phantom
measurement of source strength, discussed later. Each of these
above audits deals with afterloading equipment. There was also
one completed dosimetric audit of electronic brachytherapy in
the UK47 (unlike traditional radionuclide-based brachytherapy
sources, electronic brachytherapy utilizes bremsstrahlung X-ray
photons produced by miniature X-ray tubes operating around
50 kVp). There are likely to be many local audits, which are
not formally published, involving brachytherapy seeds. These
would generally involve comparisons of source strength de-
terminations using different well-type ionization chambers,
such as those reported by Palmer et al9 in which six centres
intercompared source strength in both 2007 and 2009, with
all results within 2.8% of the manufacturer’s source certiﬁ-
cate. There have also been conference presentations on bra-
chytherapy audit; however, those obtained were not widely
available in searchable proceedings or publications.48–50 An
IAEA survey of dosimetric audit networks in 2013 indicated
that only 13 of 53 organizations worldwide undertook audits
in brachytherapy.51 One of these organizations is the EQUAL-
ESTRO laboratory, which has provided external audits in
brachytherapy for more than 10 years. This is in the format of
an independent remote service in two steps:52 (1) a geometric
reconstruction test using the “Baltas” phantom53 to check local
techniques of geometric reconstruction used in dose calcula-
tion; followed by (2) a dosimetric test, which are described in
articles by Roue et al,41,44 and included in the discussion be-
low. The EQUAL-ESTRO laboratory is based in France, where
external audit of brachytherapy systems is not mandatory at
present, although around 10% of radiotherapy centres in France
use the service, alongwith an equal number from other European
countries (A Veres, EQUAL-ESTRO Laboratory, 2013, personal
communication). Until recently, the RPC at the MD Anderson
Cancer Centre, TX, USA, did not have remote measurement
capabilities for brachytherapy, relying instead on credentialing
audits performed by questionnaires, patient plan checks and
benchmark treatment plans.54 The recent development of a re-
mote audit tool at the RPC is discussed below.43 A summary of
dosimetric audits in brachytherapy is provided in Table 1.
One of the ﬁrst reported dosimetric audits in brachytherapy
was from Venselaar et al37 in 1994, in which 13 radiotherapy
departments in the Netherlands and Belgium participated. An
ionization chamber with an in-air jig was transported to each
centre and the reference air kerma rate compared between the
host and visiting equipment for the local Ir-192 HDR source.
Results showed a mean deviation of 11.3%, range, 20.4% to 1
3.0%, between the two measurements.
A comparison of calibration procedures for Ir-192 HDR was
conducted by de Almeida et al38 in 1999, who compared sources
at ten centres in Brazil. Uniquely for an audit methodology, all
centres were invited to bring their measuring equipment to
a single HDR treatment unit and compare their source strength
determinations. At the time, there was no national dosimetry
protocol in Brazil: six centres used in-air jigs with thimble-type
ionization chambers, four used well-type ionization chambers
and two used both methods. All results were within 63.0% (one
initially at 24.6% but subsequently resolved) of the reference
calibration system measurement.
In 2001, Elfrink et al39 reported on an audit conducted in the
Netherlands and Belgium with the stated aims to determine the
accuracy of brachytherapy implant reconstruction and dose
delivery for HDR, pulsed dose rate (PDR) or low-dose rate
(LDR) remote afterloading treatment equipment, via onsite
measurements. At the time, direct three-dimensional (3D) re-
construction of treatment applicators, using CTor MRI, was not
widely available, and two-dimensional (2D) planar X-ray image
processes were used clinically. An indication of the accuracy of
applicator reconstruction processes was assessed using a cubic
phantom containing spheres at known locations. Using the 2D
imaging system, the reconstructed relative positions of the
spheres were compared with known dimensions. The reported
average deviation was 1.3mm (60.5mm at 1 standard de-
viation), which represents the physical limitations of the imaging
and reconstruction systems; the uncertainty of reconstruction of
actual applicators within patients, rather than spheres in a solid
phantom, is likely to be larger. To determine the accuracy of
dose delivery, a solid cylindrical polymethyl methacrylate
(PMMA) phantom was used, 20 cm in diameter and 15 cm in
height, similar to the design proposed by Meertens.55 An ioni-
zation chamber placed on the axis of the cylinder was sur-
rounded by three straight line applicators at 5 cm radially from
the chamber and equally spaced at 120°, each with one dwell
position at the level of the effective point of measurement of the
chamber. Each clinic was asked to prepare a plan to deliver
a prescribed dose at the ionization chamber. A transit dose
correction was applied to the measurement to enable direct
comparison with treatment planning systems that did not make
transit corrections. The agreement between measured and
treatment planning system-calculated dose at the chamber was
found to be within 65.0% in all but one clinic, where a 6.8%
deviation was recorded and attributed to an error in the source
strength value on the source certiﬁcate. It was stated that a 2mm
error in the source position, nominally aligned with the chamber,
would result in a deviation of the measured dose of only 0.2% in
the audit conﬁguration used. Therefore, additional dwell positions
were measured at 120mm and 220mm to assess the source
position accuracy. Results stated seven clinics had source position
errors .1mm, three of which exceeded 2mm.
Heeney et al40 designed an in-air jig for Farmer-type ionization
chambers to measure the reference air kerma rate at nine clinics,
auditing ﬁve HDR units and six LDR units, in Ireland, Scotland
and the north of England. The measurement apparatus was
essentially a cruciform of acrylic material with two locations for
ionization chambers (reference and ﬁeld chambers) with a gra-
dient correction being applied and two holders for straight
treatment catheters, at variable source to detector distances.
Results showed a mean difference between the host and auditor
determination of the reference air kerma rate of 0.8% (range,
20.9% to 11.5%) for HDR units and a mean of 0.3% (range,
23.8% to 12.4%) for LDR units.
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Table 1. Summary of dosimetric audits in brachytherapy
Reference
Equipment
audited
Dosimeter used Region
Number of
audits
Results
Venselaar et al37
(1994)
HDR
Thimble-type
ionization chamber
with an in-air jig
Netherlands and
Belgium
13
Auditor compared
with local
measurement:
mean, 11.3%; range,
20.4% to 13.0%
De Almeida et al38
(1999)
HDR
Thimble-type
ionization chamber
with an in-air jig and/
or well-type
ionization chamber
Brazil 10
Visiting centres
compared with
reference
measurement:
all within 63.0%,
one error detected,
result at 24.6%,
calibration factor
Elfrink et al39 (2001)
HDR, PDR,
LDR-afterloader
Thimble-type
ionization chamber
in solid cylindrical
PMMA phantom
with three straight
catheters
Netherlands and
Belgium
33
Measured compared
with prescribed:
for HDR mean
10.9%61.3% (1SD)
for PDR mean
11.0%62.3% (1SD)
for LDR mean
11.8%62.2% (1SD)
One error
detected, LDR result at
6.8%, source strength
certiﬁcate
Heeney et al40 (2005)
HDR,
LDR-afterloader
Thimble-type
ionization chambers
custom-designed in
an air jig
Ireland, Scotland
and the north of
England
11 units at 9 clinics
Auditor compared
with local
measurement:
for HDR, mean,
10.8%; range,
20.9% to 11.5%
for PDR, mean,
10.3%; range,
23.8% to 12.4%
Roue et al41 (2007)
EQUAL-ESTRO
Laboratory
HDR, PDR
Mailed TLD with
phantom comprising
three PMMA tubes
around central
dosimeter, in water
Europe 17
Measured compared
with treatment
planning system:
range, 24.7% to
14.7%
One error detected,
calibration coefﬁcient
Carlsson Tedgren and
Grindborg42 (2008)
HDR, PDR
Well-type ionization
chamber
Sweden 14 units at 7 clinics
Auditor compared
with local
measurement:
all within 61.0%,
except one within
13%
Auditor to certiﬁcate
and local to
certiﬁcate:
range, 21.5% to
13%
Palmer et al9 (2011) I-125 seed
Mailed seed with
NPL calibration
certiﬁcate for local
well-type ionization
chamber
Central–southern
England
6 clinics, each
audited twice
Local measurement
to seed calibration
certiﬁcate
all within 62.8%
(Continued)
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In 2007, Roue et al41 published a report on the development of
a remote mailed dosimetry audit system using a custom phan-
tom and TLD. The methodology was developed by the ESTRO
BRAPHYQS Physics Network and the EQUAL-ESTRO labora-
tory and is the most signiﬁcant brachytherapy audit to date. The
audit has been available to clinics since 2004 via the EQUAL-
ESTRO Laboratory. The phantom consists of three PMMA tubes
supporting HDR treatment unit catheters at 5 cm radially from,
and equally spaced at 120° around, a central TLD holder. The
phantom has similar geometry to the equipment used by Elfrink
Table 1. (Continued)
Reference
Equipment
audited
Dosimeter used Region
Number of
audits
Results
Eaton et al47 (2013)
Electronic
intraoperative
brachytherapy
Ionization chamber,
TLD, radiochromic
ﬁlm
UK 7
Auditor compared with
local measurement:
mean output
23.2%62.7%
Other parameters
within experimental
uncertainty
Haworth et al18
(2013)
HDR, PDR
“End-to-end” audit.
TLD with phantom
comprising three
PMMA tubes around
central dosimeter, in
water
Australia 7
Measured compared
with treatment
planning system:
all results within 65%
One large error
detected (25%),
incorrect step size used
at treatment unit
compared with TPS
Casey et al43 (2013)
Radiological Physics
Centre
HDR
Optically stimulated
luminescence
nanoDots (quantity
two per
measurement) in
small mailable
polystyrene phantom
USA 8
Measured compared
with treatment
planning system:
mean, 0.0%6 1.2%
(1 SD)
Palmer et al45 (2013)
Institute of Physics
and Engineering in
Medicine
HDR, PDR
“End-to-end” audit.
Radiochromic ﬁlm
(dose distribution
and point dose),
clinical
brachytherapy
applicator in custom
Solid Water®
phantom
UK
In progress, (22/46
complete in February
2014)
Measured compared
with treatment
planning system:
full results not yet
available. Results of
ﬁrst two pilot audits:
mean distance to
agreement at Point A
is 1.26 1.1mm
(k5 2),
Mean gamma passing
rate at 3% (local),
3mm
criteria5 98.6%
Chris Lee, The
Clatterbridge Cancer
Centre (personal
communication)
HDR, PDR
Well-type ionization
chamber
UK In progress
Auditor compared
with local
measurement:
full results not yet
available. Results of
ﬁrst ﬁve centres: range,
20.1% to 10.05%.
NCRI Radiotherapy
Trials Quality
Assurance Group,
with NPL
HDR, PDR
Three stacks of alanine
and thimble-type
ionization chamber
around central source
in Solid Water and
Perspex® block
UK In progress
Results not yet
available
HDR, high dose rate; LDR, low dose rate; NPL, National Physical Laboratory, UK; PDR, pulsed dose rate; PMMA, polymethyl methacrylate; SD, standard
deviation; TLD, thermoluminescent detector; TPS, treatment planning system.
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et al39; however, instead of one dwell in each catheter, the
EQUAL-ESTRO audit uses two dwells in each to produce a ho-
mogeneous dose distribution within the cylindrical TLD de-
tection volume (20mm height, 3mm diameter). The audit was
performed by irradiating the TLD capsule to a dose of 1Gy in
the dedicated phantom whilst submerged in a water tank, with
minimum cube dimensions of 20 cm. The dosimetric audit is
based on the comparison between the dose to water measured
with the TLD and the dose calculated by the local treatment
planning system. In the 2007 article, Roue et al41 report results
from 17 audits with the ratio between the measured dose and
planned dose ranging from 0.953 to 1.047. It is reported that one
audit result was initially outside the tolerance level, with the
error being due to the use of an “inadequate calibration co-
efﬁcient”. Once rectiﬁed, the audit was repeated and a result
within tolerance was obtained. The acceptable limit used by the
EQUAL-ESTRO Laboratory for dose deviation is 7% (A Veres,
EQUAL-ESTRO Laboratory, 2013, personnal communication).
A dosimetric audit of source strength determination in Sweden
for HDR and PDR Ir-192 brachytherapy sources was reported by
Carlsson Tedgren and Grindborg42 in 2008. All 7 Swedish cen-
tres were audited, comprising 14 afterloading treatment units,
using a well-type ionization chamber with plastic transfer
catheter. The ratio of the measured reference air kerma rate by
the auditor and by the host centre to the vendor’s source cer-
tiﬁcate was determined. All ratios of measurement to certiﬁcate
were between 0.85 and 1.03, being within the 63% source
calibration uncertainty (k5 2) quoted by the vendors. The
agreement between the auditor and local determination of ref-
erence air kerma rate was all within 1%, except in one case,
which was within 3%.
The ﬁnal two publications on completed dosimetric brachyther-
apy audits were both reported in the literature in 2013 and
marked a change from prior approaches. One incorporated bra-
chytherapy imaging to assert full system test,18 and the other used
optically stimulated luminescence (OSL) dosimetry as a novel
detector for brachytherapy audit.43 The “end-to-end” brachy-
therapy audit was conducted at seven clinics in Australia, reported
by Haworth et al,18 as a pilot study to demonstrate feasibility prior
to a more complex audit to be devised. The current phantom was
based on the design described by Roue et al,41 using two source
dwell positions (630mm) in each of the three straight catheters
with a central TLD measurement in a homogeneous dose region.
The phantom was ﬁlled with water and CT imaged using normal
clinical protocols, identifying source catheters and radio-opaque
markers in the position of the central TLD. A host treatment plan
was produced to deliver 1Gy to the TLD and delivered using
normal clinical processes. All results were within the stated “op-
timal” tolerance of 65%, except one centre in which a 25% error
was reported, outside the “emergency” tolerance level. This was
caused by the use of a 5mm step size at the treatment console for
delivery, rather than the 2.5mm step size that had been used at
the treatment planning system. Once this had been rectiﬁed
a repeat audit was within the “optimal” tolerance.
OSL dosimetry was developed for use in brachytherapy dosi-
metric audit by Casey et al,43 at the RPC. A mailable phantom
was designed for centres participating in National Cancer
Institute-funded cooperative clinical trials, comprising an
83 83 10 cm3 block of polystyrene (density, 1.04 g cm23)
with a single 2mm diameter channel to admit a six French or
smaller catheter. The phantom had two slots for nanoDot OSL
dosimeters (Al2O3:C), orientated with their smallest di-
mension across the highest dose gradient, at 2 cm from the
source channel on opposite sides. Audited centres were asked
to produce treatment plans to deliver 1 Gy to a line 2 cm from
the catheter over a 5 cm active length. A correction factor was
applied for the lack of scatter in the small phantom, the limited
size being a necessity for convenient mailing. A different
scatter correction was derived for Nucletron™ (Veenendaal,
Netherlands) and Varian (Palo Alto, CA) sources, due to dif-
ferences in the sources’ physical geometry, and the correction
was also reported as being OSL dosimeter batch dependent.
Results of eight pilot audits are reported in the article by Casey
et al43 in which all RPC-measured OSL dosimeter doses were
within 2% of the host centre treatment planning system
reported dose, with a mean deviation of 0%. The stated OSL
dose measurement uncertainty was 2.4% and 2.5% (k5 2) for
Nucletron and Varian HDR sources, respectively, sufﬁcient for
the RPC to establish a 65% acceptability criterion. It is an-
ticipated the OSL mailed phantom will become the basis of
future ofﬁcial RPC audits for Ir-192 HDR brachytherapy
sources.
The dosimetric audits discussed thus far have had the objective
of accurate conﬁrmation of source strength, using straight
catheters for irradiation, with dwell patterns designed to gen-
erate homogeneous dose deposition regions at the dosimeter.
Indeed, audits have been designed to minimize the effect of
source positioning errors on the measured dose: the design by
Casey et al43 stated “variations in distal/proximal source posi-
tioning up to 10mm had minimal effect on dose measurement
accuracy”. An alternative is to audit the dose delivered in typical
clinical situations, assessing the combined effect of all uncer-
tainties on dose deposition, including dwell position length
calibration, dwell paths in treatment applicators and attenuation
by the applicators, as well as source strength calibration. This is
a more complex measurement challenge that might result in
increased uncertainty, with a lack of speciﬁcity of any errors, but
at the beneﬁt of a more “clinically realistic” dosimetric audit.
Palmer et al45 were the ﬁrst to report on the design and
implementation of a pilot “end-to-end” system audit for bra-
chytherapy, involving radiochromic ﬁlm measurement of dose
distribution around clinical treatment applicators with com-
parison with treatment planning system calculations. The test
object consisted of a near full-scatter water tank with applicator
and ﬁlm supports constructed of Solid Water®, accommodating
any typical HDR/PDR cervix treatment applicator. The appli-
cator and phantom were CT scanned and taken through the full
brachytherapy treatment process. Radiochromic ﬁlm dosimeters
were accurately held in position in four orthogonal planes
bisecting the intrauterine tube of the applicator to measure point
dose at Manchester Point A and to compare dose distribution
against DICOM RTDose ﬁle export from the treatment planning
system. Typical clinical dwell patterns and prescription doses
were used for the audit. The results from just two pilot audits are
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presented in the article by Palmer et al,45 using Co-60 and Ir-192
HDR sources, with comparison of planned and delivered dose
distributions having the mean g passing rate of 98.6% at 3%
local normalization and 3mm criteria, and the mean distance to
agreement at Point A of 1.2mm. The phantom is currently being
used (2013–2014) to audit all brachytherapy centres in the UK.
There are three other brachytherapy audits currently in progress
in the UK. Chris Lee, from The Clatterbridge Cancer Centre
NHS Foundation Trust (Wirral, UK), is leading an in-
tercomparison of well-type chamber source strength measure-
ments for Ir-192 brachytherapy units, by sending a reference
well-chamber to each centre for comparison with their own
equipment. This audit was devised following the adoption of
a new IPEM code of practice for source strength determination
using a well-type ionization chamber.56 Results from the ﬁrst
ﬁve centres had agreement between local and audit measure-
ments of source strength within the range20.1% to10.05%, all
being within 60.4% of manufacturers’ source certiﬁcate (C Lee,
The Clatterbridge Cancer Centre NHS foundation Trust, 2012,
personal communication).
The National Cancer Research Institute (NCRI) Radiotherapy
Trials Quality Assurance Group, in collaboration with the Na-
tional Physical Laboratory, are also currently auditing in the UK,
led by Patty Diez and Edwin Aird, of the Mount Vernon Cancer
Centre (Northwood, UK). The audit is being conducted as a QA
requirement for the INTERLACE clinical trial (a trial of che-
motherapy before chemoradiation for cervical cancer) (http://
www.rttrialsqa.org.uk). A pre-audit treatment planning system
calculation check precedes a dosimetric audit site visit. The
phantom consists of a Solid Water block, surrounded by Per-
spex® for full scatter, with a central straight channel to accept
a plastic transfer catheter, surrounded by three cavities for ala-
nine detectors at 20mm radial distance from the source channel,
equally spaced at 120°, and a cavity for a Farmer-type ionization
chamber, are 50mm radial distance. A series of nine dwells in
the catheter are used to irradiate the alanine detectors to 10Gy,
a high dose being required for alanine dosimetry. The phantom
uses a “three equally spaced radial positions” geometry common
with other audit phantoms,18,39,41,55 but uniquely uses three
dosimeters around a central source channel, others having used
three source channels around a single central dosimeter. This
potentially enables an assessment of radial anisotropy of the
source. Results of the audit are expected late 2014.
The ﬁnal brachytherapy audit being conducted at several centres
in the UK is based on a design described by Awunor et al,46 who
have developed an audit process for the direct reconstruction of
dwell positions in ring applicators using a universal jig and
radiochromic ﬁlm. Whilst this is not a dosimetric audit, in that no
dose measurements are made, the accuracy of dwell positions in
rings is a subject much debated and might impact on the accuracy
of clinical dose delivery. Eight ring applicators were assessed in the
pilot audit, with results showing up to 6mm deviation of the
source dwell from its expected position in a ring.
This review has considered dosimetric audits for traditional
radionuclide-based brachytherapy. Electronic brachytherapy is
an emerging technology: guidance is available from The American
Society for Radiation Oncology (ASTRO) on electronic bra-
chytherapy57 and the American Association of Physicists in
Medicine (AAPM) have formed TG-182 to provide recom-
mendations for electronic brachytherapy quality management.
Audits are particularly relevant for new techniques, and the ﬁrst
comprehensive dosimetric audit of electronic intraoperative
brachytherapy has been completed by Eaton et al.47 All seven
clinical sites in the UK were audited. An ion chamber was used
to measure the output, thermoluminescent dosemeters to mea-
sure the isotropy and radiochromic ﬁlm to measure the depth
dose. Agreement within measurement uncertainty was found
between the host and auditor for all parameters at all centres,
providing conﬁdence in delivery of this new modality.
The results of the 12 dosimetric brachytherapy audits discussed
above show that in general the average agreement between au-
ditor and local measurement, or auditor measurement and
treatment planning system calculation, is sufﬁcient to be within
stated acceptable tolerances of the audits or within clinically
acceptable parameters. This provides conﬁdence in the general
consistency of brachytherapy dosimetry at the level of source
strength, within the tolerances applied in the audits. However, in
one-third of the published audits, errors were detected at one
centre in each audit, which appears to be clinically signiﬁcant.
The majority of incorrect audits were detected in the earlier
studies. The causes of the errors were stated as calibration factor,
calibration coefﬁcient, certiﬁcate source strength, and step-size
mismatch between planning system and delivery system. Con-
sidering the reports cover a 20-year period, there are a limited
number of publications on brachytherapy audit. Results appear
to be relatively consistent through this period, but in the last year
only have audits increased in complexity from source strength or
point-dose veriﬁcation, moving to system audit including the
effect of imaging in the dosimetric assessment, and inclusion of
clinical applicators and dose distribution measurement.
THE FUTURE OF DOSIMETRIC AUDITS
IN BRACHYTHERAPY
There is no doubt that clinical and physics aspects of brachy-
therapy will continue to develop at a signiﬁcant rate, including
the realization of advanced and functional imaging in brachy-
therapy, a new era of dose calculation algorithms for brachy-
therapy and an evolution away from traditional template
planning to fully patient-speciﬁc optimization. As a result, the
scope of dosimetric audit in brachytherapy will continue to be
challenged to be ﬁt for purpose.
Dosimetric audit in brachytherapy has until recently been solely
concerned with the veriﬁcation of source strength for after-
loading equipment, especially as there had been a lack of pri-
mary standard for Ir-192 and the uncertainty of source strength
quoted by manufactures some years ago was 610%.37,58 The
uncertainty quoted by manufacturers is now often 65% at
k5 3, with their source strength measurements traceable to
national standard laboratories. The ability for local radiotherapy
clinics to determine source strength has also improved, with the
development of well-type ionization chambers designed specif-
ically for brachytherapy,59 which are more robust, less sensitive
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to positional inaccuracies and room-scatter effects, and produce
higher ionization currents than does free in-air measurements
with smaller ionization chambers.42 Early results from a UK
well-chamber intercomparison demonstrated excellent agree-
ment in source strength determination (C Lee, The Clatterbridge
Cancer Centre NHS Foundation Trust, 2012, personal com-
munication). While previous concerns of source calibration
might now essentially be resolved, which should lead to reduced
uncertainty in determination of source strength, it is important
not to abandon audit checks of this fundamental parameter, but
it does enable a shift in focus to more complex areas for audit.45
As discussed earlier, dosimetric measurements in clinical bra-
chytherapy situations are problematic and measurement
uncertainties might increase as we move closer to the clinical
treatment situation. In the future, the gold-standard dosimetric
audit may be veriﬁcation by in vivo measurement and will cer-
tainly include an “end-to-end” system approach. It is important
that brachytherapy equipment is tested under conditions other
than those used for routine calibration, and assessment of dose
distributions rather than point doses might also be required for
robust assurance of treatment dose delivery in the future, either
by measurement45 or in combination with remote plan analy-
sis.60 This is true for all forms of brachytherapy: LDR seeds,
HDR or PDR afterloading equipment, and electronic brachy-
therapy. Audit of brachytherapy procedures and infrastructure
should also be undertaken, to at least qualitatively attempt as-
sessment of the likelihood of random errors and offer any
quality improvement suggestions to mitigate risks. Otherwise,
dosimetric audit will be limited to the detection of systematic
errors that might exist in brachytherapy physics.
CONCLUSIONS
In this review, we have established the need for dosimetric audit
and discussed the limited number of publications on dosimetric
audits for brachytherapy. External dosimetric audit is recom-
mended in many authoritative documents, is a mandatory re-
quirement in many countries and is advocated by the majority of
physicists working in radiotherapy. Whether for improvements
in patient care, reassurance of accuracy, fulﬁlling a legal re-
quirement, credentialing for clinical trials, simple best-practice
approach, minimizing the risk of error, avoiding litigation or
adding security in a high-pressure environment, audit should no
doubt be extended to brachytherapy as well as the more estab-
lished procedures for external beam radiotherapy. Currently,
external quality audits in brachytherapy are not common
practice, but it is clear that future advancements in brachy-
therapy should be underpinned by the reassurance of compre-
hensive dosimetric audit. Assuring conﬁdence in the clinical
utility of brachytherapy requires many aspects of clinical audit,
of which dosimetric audit is an essential component.
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